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Background The evidence for benefits of bivalirudin 
over heparin has recently been challenged. We aimed 
to analyse the safety and cost-effectiveness following 
reintroduction of heparin instead of bivalirudin as the 
standard anticoagulation for primary percutaneous 
coronary intervention (PPCI) in a high-volume centre.
Methods and results This analysis was an open-label, 
prospective registry including all patients admitted to our 
centre for PPCI from April 2014 to April 2016. Heparin 
was reintroduced as standard anticoagulant in April 2015. 
During the 2 years, 1291 patients underwent a PPCI, 
662 in the Bivalirudin protocol period (Cohort B) and 629 
in the Heparin protocol period (Cohort H). Baseline and 
procedural characteristics were not significantly different, 
except for a higher use of thromboaspiration and femoral 
access in the earlier Cohort B. Glycoprotein 2b3a (Gp2b3a) 
antagonists were used in 24% of the patients in Cohort 
B versus 28% in Cohort H (P<0.01). We did not observe 
any differences in death at 180 days (11.03% in Cohort 
B vs 11.29% in Cohort H)(HR 95% CI 0.98 (0.72 to 1.33), 
P=0.88). The incidence of any bleeding complications at 
30 days did not differ between the two periods (21.9% vs 
21.9%, P=0.99). The cost related to the anticoagulants 
amounted to £246 236 in Cohort B versus £4483 in 
Cohort H (£324 406 vs £102 347 when adding Gp2b3a 
antagonists).
Conclusion We did not find clinically relevant changes in 
patient outcomes, including bleeding complications with 
reintroduction of heparin in our PPCI protocol. However, 
the use of heparin was associated with a major reduction 
in treatment costs.
IntroduCtIon
European and American guidelines recom-
mend intravenous anticoagulation in all 
patients undergoing primary percuta-
neous coronary intervention (PPCI).1 2 Bivali-
rudin is a specific, reversible, direct thrombin 
inhibitor, characterised by a quick onset of 
action and short half-life, overcoming the 
limitations of heparin, with a more predict-
able antithrombotic response. Harmonizing 
Outcomes with Revascularization and Stents 
in Acute Myocardial Infarction (HORI-
ZONS-AMI) and most recently the European 
Ambulance Acute Coronary Syndrome Angi-
ography (EUROMAX) trial suggested the 
superiority of bivalirudin versus the combi-
nation of heparin plus glycoprotein 2b3a 
(Gp2b3a) antagonists in patients undergoing 
PPCI. The benefit was in net adverse clinical 
events, driven mainly by the reduction of 
bleeding complications, despite a higher rate 
of stent thrombosis (ST).3 4 
Bivalirudin use in PPCI has recently been 
challenged by the results of the  Unfraction-
ated heparin versus bivalirudin in primary 
percutaneous coronary intervention (HEAT-
PPCI) trial. This single-centre randomised 
trial compared bivalirudin and unfraction-
ated heparin (UFH) with bailout Gp2b3a and 
favoured heparin with respect to ischaemic 
and bleeding outcomes.5 This trial used 
contemporary methods, including radial arte-
rial access and more potent P2Y12 blockers 
(ie, prasugrel and ticagrelor). as the default 
strategy. As a result, the most recent guide-
lines of the European Society of Cardiology 
(ESC) downgraded the recommendation to 
Key questions
What is already known about this subject?
 ► Bivalirudin is associated with reduction in the risk 
of bleeding events during primary percutaneous 
coronary intervention (PPCI) for ST elevation 
myocardial infarction (STEMI) in comparison with 
heparin versus Gp2b3a inhibitors.
 ► Recently, similar outcomes between bivalirudin and 
heparin has been showed in randomized trials, with 
higher risk of stent thrombosis with bivalirudin.
What does this study add?
 ► The present analysis showed that the 
reintroduction of heparin instead of bivalirudin 
as standard anticoagulant for PPCI did not lead 
to significant differences in efficacy or safety 
outcomes, but was associated with a significant 
cost saving.
How might this impact on clinical practice?
 ► The use of heparin should be the first line 
anticoagulant during the management of STEMI 
with PPCI.
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use bivalirudin from IB to IIA.1 Following this, Bivali-
rudin or unfractionated heparin in patients with acute 
coronary syndromes managed invasively with and without 
ST elevation (MATRIX) trial showed in the largest and 
most contemporary cohort, similar outcomes between 
heparin and bivalirudin.6
Prior to publication of the HEAT-PPCI results, the stan-
dard of care at our institution was to use bivalirudin as 
the anticoagulant of choice for PPCI, unless contraindi-
cated. Due to the changes in the ESC guidance plus the 
geographical and procedural similarities between our 
centre and the HEAT-PPCI study centre, we switched to 
heparin as our default antithrombotic agent. We prospec-
tively assessed clinical outcomes, including bleeding 
complications and treatment costs.
The objective of the present study was to investigate 
the differences in clinical outcomes and financial costs 
following the reintroduction of heparin as the standard 
anticoagulant in patients treated for PPCI in our high-
volume centre.
MaterIals and MetHods
study design and patients
This analysis was an open-label, single-centre, prospective 
registry undertaken at the Bristol Heart Institute, Bristol, 
UK. All patients undergoing PPCI from April 2014 to 
April 2016 were prospectively enrolled.
Two periods were defined: Cohort B encompassed all 
PPCI patients admitted from 1 April 2014 to 30 March 
2015. During this period, bivalirudin was used as the stan-
dard for anticoagulation in PPCI, unless contraindicated. 
Cohort H included patients treated by PPCI between 1 
April 2015 and 1 April 2016 following an institutional 
protocol amendment resulting in the use of UFH as the 
standard periprocedural anticoagulant.
The indication for PPCI was based on the current guid-
ance from the ESC.1 All patients, including out-of-hospital 
cardiac arrest, intubated patients and cardiogenic shock, 
were included in the main analysis. A prespecified anal-
ysis was planned in the cohort of non-ventilated patients.
treatment
Bivalirudin was started as soon as possible during the 
PPCI and was given as a bolus of 0.75 mg per kg of body 
weight, followed by an infusion of 1.75 mg per kg per 
hour for 4 hours following the procedure.1 Heparin was 
given at a dosage of 70–100 IU per kg (operator prefer-
ence) and then guided by activated clotting time (ACT) 
results, aiming to maintain an ACT of >250 s.
Bailout use of a Gp2b3a inhibitor was allowed in the 
event of high thrombus burden or microvascular obstruc-
tion (no reflow), as recommended in ESC guidelines.1 
Any Gp2b3a inhibitor could be used at the approved 
doses and regimens.
During the index admission, a 300 mg loading dose of 
aspirin was given to patients who were treatment naïve 
before the study. All patients were pretreated with a 
loading dose of clopidogrel 600 mg, ticagrelor 180 mg or 
prasugrel 60 mg before or during the PPCI. The use of 
prasugrel and ticagrelor was recommended over clopido-
grel unless contraindicated, but the choice was left to the 
treating physician. Other cardiac medications were given 
according to ESC guidelines.1
Follow-up and endpoint assessments
We aimed to assess the incidence of death, cerebrovas-
cular accident (CVA), target lesion failure (TLF), definite 
ST and bleeding at 30 days. Additionally, the mortality 
rate was evaluated again at 6 months.
TLF was defined as any unexpected coronary revas-
cularisation procedure (PCI or coronary artery bypass 
graft surgery) or reinfarction of the target lesion during 
the follow-up period. A diagnosis of CVA was made by 
a treating neurologist. CT or MRI was used to distin-
guish ischaemic from haemorrhagic strokes. Definite 
ST was classified according to the Academic Research 
Consortium criteria.7 Bleeding episodes were classified 
according to the Bleeding Academic Research Consor-
tium (BARC) classification.8
All data were collected prospectively using standardised 
questionnaire and were entered into a central database. 
Follow-up was planned for 6 months after inclusion or 
until the time of death, whichever came first.
All events were adjudicated by a local research 
committee that was unaware of treatment allocations. All 
thrombotic and bleeding events requiring medical atten-
tion were verified by research nurses who were blinded 
to the patient’s study group by use of medical records 
obtained from referring family doctors and hospitals.
Cost analysis
All costs were expressed in Great British Pound. The 
exact dosages of anticoagulants and Gp2b3a inhibitors 
administrated during the hospitalisation were reported, 
for each patient and procedure, by analysis of the 
medical and drug charts. We used the drug cost at our 
institution as primary base-case estimate: a 20 mL heparin 
phial costs £4.20, a bivalirudin 250 mg/5 mL phial costs 
£372, a 12.5 mg/50 mL tirofiban phial costs £146.10 and 
a 10 mg/5 mL abciximab phial costs £265.60. The other 
antithrombotic costs were assumed to be negligible 
and equal for all agents. We aimed to define the cost of 
antithrombotic agents associated with the PPCI index 
procedure.
statistical analysis
All calculations were performed using SPSS software 
(version 20.00) and GraphPad prism (version 7.0). 
Continuous variables were reported as means and SD 
or as medians and range (according to their distribu-
tion), and categorical variables were reported as count 
and percentages. Standard two-sided tests were used to 
compare continuous characteristics (Student's t-tests 
or Mann-Whitney U-tests) or categorical characteristics 
(χ2 or Fisher's exact tests) among patient groups. As a 
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measure of strength of the treatment effect, we calcu-
lated HR and 95% CI for ‘Cohort B’ versus ‘Cohort H’ 
by means of Cox’s proportional hazards regression anal-
ysis.





Age, mean (SD), years 65.6±12.9 64.6±13.3 0.15
Body mass index, mean (SD) 28.6±21.7 28.5±17.3 0.93
Male gender, n (%) 473 (71.5%) 483 (76.8%) 0.03
Medical history, n (%)
  Coronary artery disease 152 (23.0%) 134 (21.3%) 0.47
  Myocardial infarction 113 (17.1%) 92 (14.6%) 0.23
  CABG 23 (3.5%) 20 (3.2%) 0.77
  Coronary revascularisation 88 (13.3%) 74 (11.8%) 0.41
  Stroke/TIA >1 year 29 (4.4%) 16 (2.5%) 0.07
  Peripheral arterial disease 31 (4.7%) 25 (4.0%) 0.21
  Congestive heart failure 6 (0.9%) 7 (1.1%) 0.71
  Hypertension 354 (53.5%) 303 (48.2%) 0.06
  Hypercholesterolaemia 307 (46.4%) 294 (46.7%) 0.90
  Diabetes 101 (15.3%) 83 (13.2%) 0.29
  Current smoker 216 (32.6%) 248 (39.4%) 0.01
Long-term antiplatelet therapy, n (%)
  Aspirin 256 (38.7%) 243 (38.6%) 0.99
EKG presentation, n (%)
  ST elevation 640 (96.7%) 608 (96.7%) 0.99
  LBBB 10 (1.5%) 7 (1.1%) 0.53
EKG territory of infarction, n (%)
  Anterior 223 (33.7%) 229 (36.4%) 0.31
Cardiogenic shock, n (%) 82 (12.4%) 77 (12.2%) 0.94
Ventilated patients, n (%) 59 (8.9%) 57 (9.1%) 0.93
Out-of-hospital cardiac arrest, n (%) 69 (10.4%) 66 (10.5%) 0.97
Anticoagulation, n (%)
  Bivalirudin 498 (75.2%) 5 (0.8%) <0.01
  Heparin 164 (24.8%) 624 (99.2%) <0.01
Recent lysis, n (%) 1 (0.2%) 0 (0%)
Gp2b3a agent, n (%) 154 (22.3%) 177 (28.1%) 0.05
  Tirofiban 38 (5.7%) 22 (3.5%) 0.06
  Abciximab 116 (17.5%) 155 (24.6%) <0.01
Loading dose of antiplatelet, n (%) 633 (95.6%) 611 (97.1%) 0.15
Antiplatelet therapy received between randomisation and discharge, n (%)
  Aspirin 652 (98.5%) 617 (98.1%) 0.58
Oral P2Y12 blocker, n (%)
  Clopidogrel 134 (20.2%) 75 (11.9%) <0.01
  Prasugrel 411 (62.1%) 362 (57.6%) 0.10
  Ticagrelor 117 (17.7%) 192 (30.5%) <0.01
CABG, coronary artery bypass graft; Gp2b3a, glycoprotein 2b3a; LBBB, left bundle branch block.; TIA, transient ischaemic attack.
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results
Baseline
Between April 2014 and April 2016, we enrolled 1291 
patients, of whom 662 were included in Cohort B and 
629 in Cohort H. Baseline and procedural characteristics 
are presented in tables 1 and 2. In Cohort B, 75.2% of 
the patients were treated with bivalirudin while 24.8% 
received heparin. In Cohort H, 99.2% of patients had 
heparin and 0.8% received bivalirudin. One thousand 
one hundred and seventy-five (91.0%) patients were 
enrolled in the non-ventilated cohort, corresponding to 
603 in Cohort B and 572 in Cohort H.
Regarding the antiplatelet strategy, we observed that 
clopidogrel was less frequently used in Cohort H (11.9% 
vs 20.2%, P<0.01). The use of Gp2b3a inhibitors was 
higher in Cohort H (28.1% vs 22.3%, P=0.05), mostly 
driven by more frequent use of abciximab (24.6% vs 
17.5%, P<0.01).
Regarding the procedural characteristics, the femoral 
access was less frequently used in Cohort H (12.6% vs 
19.8%, P<0.01). We observed significant difference in the 
use of mechanical thrombus aspiration with a significant 
drop in the later Cohort H (44.9% vs 12.4%, P<0.01).
endpoints
At 30 days, any ischaemic endpoint occurred in 72 
(10.9%) patients in Cohort B and in 67 (10.7%) in 
Cohort H (HR 95% CI 1.02 (0.72 to 1.46), P=0.90).
At 30 days, 62 (9.4%) patients died in Cohort B versus 
56 (8.9%) in Cohort H (HR 95% CI 1.05 (0.75 to 1.49), 
P=0.77) (table 3, figure 1). At 180 days, 73 (11.03%) 
patients died in Cohort B versus 71 (11.3%) in Cohort 
H (HR 95% CI 0.98 (0.72 to 1.33), P=0.88) (table 3, 
figure 1).
TLF was observed at 30 days in 12 (1.8%) patients 
in Cohort B and 11 (1.8%) in Cohort H (HR 95% CI 
1.03. (0.46 to 2.33), P=0.93); a CVA event at 30 days was 
observed in five (0.8%) patients in Cohort B and three 
(0.5%) patients in Cohort H (HR 95% CI 1.58 (0.38 to 
6.60), P=0.52) (table 3, figure 1). The rate of definite 
ST at 30 days was low and not different between the two 
groups (three (0.5%) patients in Cohort B vs two (0.3%) 
in Cohort H, P=0.70).
Bleeding events defined as all BARC occurred in 
145 (21.9%) patients in Cohort B and in 138 (21.9%) 
in Cohort H (HR 95% CI 0.99 (0.91 to 1.23), P=0.99) 
(table 3, figure 2). Bleeding events defined as BARC ≥2 
occurred in 102 (15.4%) patients in Cohort B and in 115 





Access site, n (%)
  Femoral 131 (19.8%) 79 (12.6%) <0.01
Culprit lesion, n (%) 0.60
  LMS 16 (2.2%) 24 (3.4%) 0.18
  LAD 270 (37.8%) 272 (38.9%) 0.91
  LCx 127 (17.8%) 126 (18.0%) 0.92
  RCA 289 (40.5%) 264 (37.7%) 0.29
  Graft 12 (1.7%) 14 (2.0%) 0.66
Number of bystander lesions (n %)* 390 (35.3%) 308 (30.6%) 0.02
Number of lesions attempted (n %)* 822 (74.5%) 834 (82.7%) <0.01
Number of stents per patient, mean (SD) 1.3±0.8 1.4±0.9 0.01
Drug eluting stent, (n %)† 815 (95.5%) 866 (97.6%) 0.02
Stent diameter, mean (SD) 3.3±0.7 3.4±1.5 0.11
Stent length, mean (SD) 27.1±10.2 27.8±11.2 0.09
TIMI flow in the culprit artery at the end of the procedure, n (%)‡: 0.17
  0–1 20 (2.8%) 12 (1.7%)
  2–3 694 (97.2%) 688 (98.3%)
Number of lesions successful, n (%)§: 793 (96.5%) 799 (95.8%) 0.48
Use of a thrombus extraction catheter, n (%): 297 (44.9%) 78 (12.4%) <0.01
Use of a vascular closure device system, n (%)¶: 107 (81.7%) 76 (96.2%) <0.01
Thrombotic procedural complications, n (%): 21 (3.17%) 13 (2.07%) 0.22
If more than one stent is used, the stent length denotes the sum of all stent lengths.
LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery; LMS, left main stem; RCA,right coronary artery.
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patients (18.3%) in Cohort H (HR 95% CI 0.84 (0.66 to 
1.08), P=0.17).
When we directly compare heparin versus bivali-
rudin during the whole period, any ischaemic endpoint 
occurred in 89 (11.2%) patients on heparin and in 50 
(9.9%) on bivalirudin (HR 95% CI 1.14 (0.82 to 1.56), 
P=0.44) at 30 days. Bleeding all BARC was observed in 
180 patients (22.8%) on heparin versus 103 (20.5%) 
on bivalirudin (HR 95% CI 1.12 (0.90 to 1.38), P=0.32), 
while bleeding BARC 2–5 was observed in 150 (19.0%) 
versus 67 (13.3%) patients (HR 95% CI 1.43 (1.10 to 
1.86), P=0.001).
When the analysis was restricted to non-ventilated 
patients, we observed that at 30 days 36 (6.0%) patients 
died in Cohort B versus 30 (5.2%) in Cohort H (HR 
95% CI 1.14 (0.71 to 1.82), P=0.59). At 180 days, 44 (7.3%) 
patients died in Cohort B versus 43 (7.5%) in Cohort H 
(HR 95% CI 0.97 (0.65 to 1.46), P=0.89) (table 4).
TLF at 30 days was observed in 12 (2.0%) patients in 
Cohort B and 9 (1.6%) in Cohort H (HR 95% CI 1.27 
(0.53 to 2.98), P=0.59); a CVA event at 30 days was 
observed in one (0.2%) patient in Cohort B and two 
(0.4%) patients in Cohort H (HR 95% CI 0.47 (0.04 
to 5.22), P=0.53.). Definite ST at 30 days was reported 
in three patients in Cohort B versus one in Cohort H 
(P=0.34). Bleeding events defined as all BARC occurred 
in 132 (21.9%) patients in Cohort B and in 114 (19.9%) 
in Cohort H (HR 95% CI 1.21 (0.97 to 1.69), P=0.10) 
(table 4). Bleeding events defined as BARC ≥2 occurred 
in 91 (15.1%) patients in Cohort B and in 92 patients 
(16.1%) in Cohort H (HR 95% CI 0.94 (0.72 to 1.23), 
P=0.64).
Table 3 Endpoints at 30 and 180 days in the whole cohort
Cohort B Cohort H P value
Death 30 days 62 (9.4%) 56 (8.9%) 0.77
Death 180 days 73 (11.0%) 71 (11.3%) 0.88
CVA 30 days 5 (0.8%) 3 (0.5%) 0.52
TLF 30 days 12 (1.8%) 11 (1.8%) 0.93
Definite ST 30 days 3 (0.5%) 2 (0.3%) 0.70
Bleeding all 30 days 145 (21.9%) 138 (21.9%) 0.99
Bleeding BARC≥2 30 days 102 (15.4%) 115 (18.3%) 0.17
Bleeding BARC 2 30 days 82 (12.4%) 99 (15.7%) 0.09
Bleeding BARC 3 30 days 17 (2.6%) 15 (2.4%) 0.83
Bleeding BARC 4 30 days 1 0 – 
Bleeding BARC 5 30 days 2 1 – 
CVA, cerebrovascular accident; ST, stent thrombosis; TLF, target lesion failure.
Figure 1 Incidence of ischaemic endpoints at 30 and 180 days. CVA, cerebrovascular accident; ST, stent thrombosis; TVF, 
target vessel failure.
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Cost analysis
The total costs related to the anticoagulants used for 
the index procedure in Cohort B were £2 46 236.0 versus 
£4483.0 in Cohort H (P<0.01), corresponding to £372.0 
per patient versus £7.1 per patient (figure 3A). When 
we added the cost of Gp2b3a inhibitors, the difference 
remained significant with £324 406.0 in Cohort B versus 
£102 347.0 in Cohort H (P<0.01), corresponding to 
£490.0 per patient versus £162.7 per patient (figure 3B).
dIsCussIon
We report ‘real-world’ adoption of the latest evidence in 
acute antithrombotic therapy in PPCI and have demon-
strated significant cost savings through the reintroduction 
of UFH use with comparable ischaemic and bleeding 
outcomes.
HORIZONS-AMI was the first randomised trial to show 
the superiority of bivalirudin (administered without 
a post-PPCI infusion) versus heparin plus Gp2b3a, in 
patients undergoing PPCI, on net adverse clinical events, 
driven mostly by the reduction of bleeding complica-
tions.3 More recently, EUROMAX confirmed the reduc-
tion in the composite endpoint of bleeding plus death 
with bivalirudin (administered with a post-PPCI infusion) 
versus heparin plus optional Gp2b3a antagonists (11.5% 
vs 69% of patients had Gp2b3a inhibitors, respectively).4 
A higher rate of ST was observed with use of bivalirudin in 
both trials.3 4 HORIZONS-AMI demonstrated a mortality 
benefit with bivalirudin use, which was not confirmed 
in EUROMAX. In contrast, HEAT-PPCI, a single- centre 
randomised trial, investigated bivalirudin (without 
post-procedure infusion) versus low-dose heparin (70 IU 
per kg), limiting Gp2b3a use to bailout in both groups 
(13% in each group).5 The incidence of the primary isch-
aemic endpoint (all-cause mortality, stroke, recurrent 
infarction and unplanned target lesion revascularisation) 
was higher in the bivalirudin group. Interestingly, bivali-
rudin failed to prove a significant reduction in bleeding 
complications (12.5% vs 13.5%, P=0.54).
Since then, Bavarian Reperfusion Alternatives Evalu-
ation 4 trial compared prasugrel plus bivalirudin versus 
clopidogrel plus heparin in PPCI and was stopped 
prematurely due to slow recruitment and failure to 
demonstrate differences in outcome.9 The BivaliRudin 
in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa 
and Heparin: a Randomised Controlled Trial, a Chinese 
randomised trial, compared bivalirudin versus heparin 
plus Gp2b3a in PPCI, with a reduction of net adverse clin-
ical events with bivalirudin.10 Most recently, the MATRIX 
randomised trial showed in 7213 patients with acute 
coronary syndrome (ACS) (of whom 55.6% underwent 
PPCI) no differences between bivalirudin and heparin 
Figure 2 Incidence of bleeding endpoints at 30 days.
Table 4 Endpoints at 30 and 180 days in the non-ventilated cohort
Cohort B Cohort H P value
Death 30 days 36 (6.0%) 30 (5.2%) 0.59
Death 180 days 44 (7.3%) 43 (7.5%) 0.89
CVA 30 days 1 (0.2%) 2 (0.4%) 0.53
TLF 30 days 12 (2.0%) 9 (1.6%) 0.59
Definite ST 30 days 3 (0.5%) 1 (0.2%) 0.34
Bleeding all 30 days 132 (21.9%) 114 (17.9%) 0.10
Bleeding BARC≥2 30 days 91 (15.1%) 92 (16.1%) 0.64
Bleeding BARC 2 30 days 78 (12.9%) 83 (14.5%) 0.09
Bleeding BARC 3 30 days 10 (1.7%) 9 (1.6%) 0.83
Bleeding BARC 4 30 days 1 0 – 
Bleeding BARC 5 30 days 2 0 – 
CVA, cerebrovascular accident; ST, stent thrombosis; TLF, target lesion failure.
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regarding the ischaemic outcomes, while bivalirudin 
significantly reduced the bleeding complication rates.6
The conflicting results of these studies, complexity 
of study designs, with mandatory/discretionary use 
of Gp2b3a inhibitors, variations in bivalirudin proto-
cols and geographical differences in clinical practice 
(particularly radial access use) have led to confusion 
surrounding the optimal antithrombotic regime for 
PPCI. However, the results of HEAT-PPCI were embraced 
by UK interventional cardiologists and have resulted in 
significant reductions in the use of bivalirudin for PPCI. 
Our results support the results observed by the HEAT-
PPCI investigators with no observed differences in isch-
aemic or bleeding endpoints with use of heparin versus 
bivalirudin. However, we noticed that the reintroduction 
of UFH was associated with an increased use of bailout 
Gp2b3a inhibitors compared with routine use of bivali-
rudin with a post-PCI infusion. This finding may have 
been accentuated by the significant reduction in the use 
of thromboaspiration catheters and potential increased 
presence of thrombus between cohorts, precipitated by 
the reporting of the findings of the The Trial of Routine 
Aspiration Thrombectomy with PCI versus PCI Alone in 
Patients with STEMI (TOTAL) study11 contributing to 
the increase of bailout Gp2b3a antagonists use.
The increase in ST incidence observed in HORI-
ZONS-AMI and EUROMAX was confirmed in HEAT-
PPCI (3, 4 and 5). Our local approach of administering 
bivalirudin as a bolus followed by a prolonged post-PPCI 
infusion was associated with very low levels of definite ST, 
with no significant difference observed in comparison 
with UFH. Interestingly, in the prespecified analysis of the 
MATRIX cohort including 55.6% of PPCI, the prolonged 
infusion did not impact the ST risk in comparison with 
no post-PPCI infusion.6
Nowadays, prasugrel and ticagrelor are the recom-
mended first-line antiplatelet agents in PPCI, in asso-
ciation with aspirin and intravenous anticoagulants.1 
Trial to Assess Improvement in Therapeutic Outcomes 
by Optimizing Platelet Inhibition with Prasugrel –
Thrombolysis in Myocardial Infarction and PLATelet 
inhibition and patient Outcomes trials proved their supe-
riority over clopidogrel in reducing ischaemic compli-
cations.12 13 However, enhanced potency of antiplatelet 
effect is associated with an increase in bleeding risk.12 13 
The initial benefit of bivalirudin was proved mostly in 
clopidogrel-treated patients.3 4 Our modern cohort used 
preferentially the newer P2Y12 inhibitors in PPCI and 
confirmed that even if numerically lower rate of bleeding 
complications was observed in the bivalirudin period, no 
significant difference was shown between both protocols 
despite a very high use of prasugrel and ticagrelor.
Nowadays, cost-effectivenes of the procedures has 
to be considered. The incidence of STEMI requiring 
PPCI remains stable and remains a significant challenge 
in health systems.1 2 Bivalirudin has been proved to be 
cost-effective in comparison with heparin plus systematic 
Gp2b3a antagonist in PPCI setting.14 Recent changes 
in PPCI treatment, including high rate of radial access 
and bailout Gp2b3a use, have highlighted the need to 
re-evaluate the cost-effectiveness of these strategies. We 
confirmed that the reintroduction of heparin as standard 
anticoagulant for PPCI was associated with significant cost 
saving that was maintained despite a slightly higher rate 
of Gp2b3a antagonist use. Additionally, clinical outcomes 
were not influenced by the anticoagulant strategy.
limitations
The present study has some limitations. First, the 
intrinsic limitations of this study result from the observa-
tional character of a prospective registry, with unadjusted 
baseline differences existing between the two cohorts. 
The two groups compared were treated at different time 
points, with the Heparin group H the year after the Bival-
irudin group B. In the group B, a significant proportion 
of patients were treated with heparin as per individual 
treatment choice in higher risk patients. Secondarily, we 
observed higher rates of radial access and newer P2Y12 
Figure 3 (A) Procedural anticoagulant cost analysis. (B) Procedural anticoagulants and glycoprotein 2b3a (Gp2b3a) inhibitors 
cost analysis.
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blockers use in the later cohort, likely related to progres-
sive adoption of PPCI recommendations.1 2 Vascular 
closure systems being largely used nowadays when 
femoral access is needed and the decrease in terms of 
use of femoral route may have impacted the cost of the 
procedure. However, this cost is not dependent on the 
subject of interest for this analysis (ie, periprocedural 
antithrombotic strategy). Similarly, the decrease in the 
use of clopidogrel and parallel increase in the use of 
ticagrelor have an obvious impact in terms of cost but 
only when extrapolated to 1-year treatment cost. When 
focusing on the procedure, it does not appear to be rele-
vant. Therefore, we decided not to include those prices in 
the analysis. Third, we included all PPCI patients referred 
to our centre, which include a substantial number of 
patients with cardiogenic shock and comatose patients. 
This explains the high rates of death at 6 months, 
compared with clinical trials. Fourth, major changes in 
PPCI techniques occurred during the planned follow-up 
period. TOTAL results confirmed the lack of benefit asso-
ciated with manual thromboaspiration devices in PPCI, 
explaining the significant differences in use of this tech-
nique between the two cohorts. Finally, we were not able 
to provide exact duration of bivalirudin infusion for each 
patient. The recommended protocol was an infusion of 3 
–4 hours post PPCI.
ConClusIon
In conclusion, in the present analysis, we observed that 
the reintroduction of heparin instead of bivalirudin as 
standard anticoagulant for PPCI did not lead to signifi-
cant differences in efficacy or safety outcomes, but was 
associated with a significant cost saving.
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